Chiral drugs: comparison of the pharmacokinetics of [ 11 C] d-threo and l-threo -methylphenidate in the human and baboon brain
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Methylphenidate (Ritalin) is the most commonly prescribed psychoactive medication for children in the US where it is used for the treatment of attention deficit hyperactivity disorder. Methylphenidate is marketed as a racemic mixture of the d-threo and l-threo enantiomers. It is believed that the d enantiomer is responsible for the therapeutic effect of methylphenidate. In this study we labeled the individual enantiomers with carbon-11 and compared their binding and pharmacokinetics in the human and baboon brain. Microdialysis studies in the rat were performed to compare their potency in elevating striatal dopamine concentration. Positron emission tomographic (PET) studies with [11C]d-threo-methylphenidate ([11C]d-threo-MP) demonstrated highest regional uptake in basal ganglia. In contrast, [11C]l-threo-methylphenidate ([11C]l-threo-MP) displayed similar uptakes in all brain regions. The ratios of distribution volumes at the steady-state for the basal ganglia to cerebellum (DVBG/DVCB) ranged from 2.2 to 3.3 for [11C]d-threo-MP in baboon and human, and only 1.1 for [11C]l-threo-MP. Pretreatment with unlabeled methylphenidate (0.5 mg/kg) or GBR12909 (1.5 mg/kg) markedly reduced the striatal but not the cerebellar uptake of [11C]d-threo-MP, whereas there was no effect on DVBG/DVCB for [11C]l-threo-MP. In the rat, d-threo-MP increased extracellular dopamine concentration by 650% whereas l-threo-MP did not affect dopamine levels. These results indicate that pharmacological specificity of MP resides entirely in the d-threo isomer and directly show that binding of the l-isomer in human brain is mostly nonspecific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cocaine Receptors on Dopamine Transporters Are Related to Self-Administration of Cocaine
Ritz, M. C., Lamb, R. J., Goldberg, S. R., & Kuhar, M. J. (1987) · Science · doi:10.1126/science.2820058 · Cited by 2,180 · cited 1×
“However, it has been shown that d-threo-MP is more potent in the induction of locomotor activity and has a higher affinity for the dopamine transporter than l-threo-MP (Barkely 1977; Schweri et al. 1985; Patrick et al. 1987; Ritz et al. 1987; Pan et al. 1994).”
BackgroundLogan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Bendriem, B., Gatley, S. J., et al. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.127 · Cited by 1,479
Self-citationHyperactive Boys Almost Grown Up: I. Psychiatric Status
Gittelman, R. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790330017002 · Cited by 977
A REVIEW OF STIMULANT DRUG RESEARCH WITH HYPERACTIVE CHILDREN
Barkley, R. A. (1977) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.1977.tb00425.x · Cited by 541 · cited 1×
“Attention deficit hyperactivity disorder (ADHD), which is estimated to affect more than 2 million children (or 3‐5%), has become America’s no. 1 childhood psychiatric disorder ( Barkley 1977 ).”
BackgroundImaging endogenous dopamine competition with [11C]raclopride in the human brain
Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Schlyer, D., Hitzemann, R., Lieberman, J., Angrist, B., Pappas, N., MacGregor, R., et al. (1994) · Synapse · doi:10.1002/syn.890160402 · Cited by 379
Self-citationZetterström, T., Sharp, T., Collin, A. K., & Ungerstedt, U. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90110-0 · Cited by 378 · cited 1×
“The mechanism(s) which make methylphenidate work for ADHD patients is still unclear, though it has been suggested that the stimulant appears to increase the level of extracellular dopamine in the frontal lobe of the brain ( Zetterstrom et al. 1988; Butcher et al. 1991; Volkow et al. 1994), where it regulates attention…”
BackgroundThe dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action
Andersen, P. H. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90363-4 · Cited by 346
FERRIS, R. M., TANG, F. L. M., & MAXWELL, R. A. (1972) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29222-9 · Cited by 301
PET evaluation of the dopamine system of the human brain.
Volkow, N. D., Fowler, J., Sj, G., Logan, J., Wang, G., Ding, Y., & Dewey, S. L. (1996) · PubMed · Cited by 299
Self-citationDopamine transporters decrease with age.
Volkow, N. D., Ding, Y., Fowler, J. S., Wang, G., Logan, J., Gatley, S. J., Hitzemann, R., Smith, G., Fields, S. D., & Gur, R. C. (1996) · PubMed · Cited by 262
Self-citation
Cited by
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Faraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631
“…NE to bind to their respective transporters (i.e., the DAT or NET) or to DA or NE receptors, as evidenced by reductions in ligand binding in PET and SPECT studies (Ding et al., 1997; Dresel et al., 1999; Gatley et al., 1999; Nikolaus et al., 2005, Nikolaus et al., 2007, 2011; Volkow et al., 1999a).”
Methylphenidate: Its Pharmacology and Uses
CHALLMAN, T. D., & LIPSKY, J. J. (2000) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)64618-1 · Cited by 553
Volkow, N. D., Wang, G.-J., Fowler, J. S., & Ding, Y.-S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.006 · Cited by 368
Self-citationAttention-Deficit/Hyperactivity Disorder and Attention Networks
Bush, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.120 · Cited by 358
“Pioneering PET work by Volkow and colleagues has showed the specific activity of MPH’s d-enantiomer in the basal ganglia (Ding et al, 1997), that oral MPH blocks the DAT with a time course matching behavioral effects (Volkow et al, 1998), and that MPH increases extracellular dopamine in the…”
BackgroundMechanism of action of methylphenidate: Insights from PET imaging studies
Volkow, N. D., Fowler, J. S., Wang, G., Ding, Y., & Gatley, S. J. (2002) · Journal of Attention Disorders · doi:10.1177/070674370200601s05 · Cited by 353
Self-citationTeo, S., Stirling, D., Thomas, S., Hoberman, A., Kiorpes, A., & Khetani, V. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00338-4 · Cited by 347
Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans
Volkow, N. D., Fowler, J. S., & Wang, G.-J. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300406 · Cited by 315
“blockade is likely due to D-threo-methylphenidate since Lthreo-methylphenidate shows no binding to DAT, nor does it increase DA (Ding et al., 1997).”
BackgroundSelf-citationCingulate, Frontal, and Parietal Cortical Dysfunction in Attention-Deficit/Hyperactivity Disorder
Bush, G. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.022 · Cited by 304
Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder
Swanson, J., Castellanos, F. X., Murias, M., LaHoste, G., & Kennedy, J. (1998) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(98)80150-5 · Cited by 275
Wilens, T. E. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318173312f · Cited by 269
“Studies in humans have shown that both oral and intravenous MPH is taken up by the brain, with d-threoMPH, but not l-threo-MPH, binding specifically to DAT proteins.(28) Studies in human and baboon brains show that binding of d-threo-MPH is concentrated in the basal ganglia, whereas there are comparatively low levels…”
BackgroundElectroencephalographic Biofeedback in the Treatment of Attention-Deficit/Hyperactivity Disorder
Monastra, V. J., Lynn, S., Linden, M., Lubar, J. F., Gruzelier, J., & LaVaque, T. J. (2005) · Applied Psychophysiology and Biofeedback · doi:10.1007/s10484-005-4305-x · Cited by 256
“This appears to be due to recent advances in molecular biology, which has revealed that stimulant medications produce their clinical effects by occupying dopamine reuptake transporters, thereby increasing the availability of dopamine at the synaptic level (Ding et al., 1997; Volkow et al., 1995).”
BackgroundHannestad, J., Gallezot, J.-D., Planeta-Wilson, B., Lin, S.-F., Williams, W. A., van Dyck, C. H., Malison, R. T., Carson, R. E., & Ding, Y.-S. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.017 · Cited by 236
Self-citationVolkow, N. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00104-9 · Cited by 217
Self-citationSpencer, T. J., Biederman, J., E. Ciccone, P., Madras, B. K., Dougherty, D. D., Bonab, A. A., Livni, E., Parasrampuria, D. A., & Fischman, A. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.387 · Cited by 206
“We measured plasma d-methylphenidate because this enantiomer has been shown to be the active moiety (15).”
BackgroundCastells, X., Ramos-Quiroga, J. A., Rigau, D., Bosch, R., Nogueira, M., Vidal, X., & Casas, M. (2011) · CNS Drugs · doi:10.2165/11539440-000000000-00000 · Cited by 197
Lower, E. E., Fleishman, S., Cooper, A., Zeldis, J., Faleck, H., Yu, Z., & Manning, D. (2009) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.03.011 · Cited by 197
Methylphenidate Is Stereoselectively Hydrolyzed by Human Carboxylesterase CES1A1
Sun, Z., Murry, D. J., Sanghani, S. P., Davis, W. I., Kedishvili, N. Y., Zou, Q., Hurley, T. D., & Bosron, W. F. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067116 · Cited by 187
“Some in vivo studies supported that the higher clinical activity of d-methylphenidate is due to its higher potency for the dopamine transporter (Ding et al., 1997: Challman and Lipsky, 2000).”
BackgroundMechanism of action of agents used in attention-deficit/hyperactivity disorder.
Wilens, T. E. (2006) · PubMed · Cited by 208
Markowitz, J. S., Straughn, A. B., & Patrick, K. S. (2003) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.12.1281.32697 · Cited by 174
Swanson, J. M., & Volkow, N. D. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00433-8 · Cited by 173
Self-citationA Strategy for Removing the Bias in the Graphical Analysis Method
Logan, J., Fowler, J. S., Volkow, N. D., Ding, Y. S., Wang, G.-J., & Alexoff, D. L. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200103000-00014 · Cited by 169
“An arterial input function was measured for both tracers and plasma samples were analyzed for unchanged tracer (see Ding et al. (1997) and Volkow et al. (1993) for plasma sampling protocols).”
MethodSelf-citationSpencer, T. J., Adler, L. A., McGough, J. J., Muniz, R., Jiang, H., & Pestreich, L. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.032 · Cited by 162
The role of neuroimaging in Parkinson’s disease
Bidesi, N., Andersen, I. V., Windhorst, A. D., Shalgunov, V., & Herth, M. M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15516 · Cited by 171
“The latter category includes, for example, two non- tropane DAT tracers: [11C]- d- threo- methylphenidate (Ding et al., 1997) and the norepinephrine transporter- preferring [11C]nomifensine (Aquilonius et al., 1987; Tatsumi et al., 1997).”
BackgroundPalliative Uses of Methylphenidate in Patients With Cancer: A Review
Rozans, M., Dreisbach, A. W., Lertora, J. J. L., & Kahn, M. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.335 · Cited by 145
PET and drug research and development.
Fowler, J. S., Volkow, N. D., Wang, G., Ding, Y., & Dewey, S. L. (1999) · PubMed · Cited by 143
Self-citationHardy, S. E. (2009) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2009.02.006 · Cited by 136
A review of microdialysis sampling for pharmacokinetic applications
Davies, M. I. (1999) · Analytica Chimica Acta · doi:10.1016/s0003-2670(98)00633-3 · Cited by 129
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Dewey, S. L., Hitzemann, R., Gifford, A. N., & Pappas, N. R. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37918-2 · Cited by 125
Self-citationHeal, D. J., & Pierce, D. M. (2006) · CNS Drugs · doi:10.2165/00023210-200620090-00002 · Cited by 135
Heal, D. J., Smith, S. L., Kulkarni, R. S., & Rowley, H. L. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.03.016 · Cited by 105
Monastra, V. J. (2005) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2004.07.004 · Cited by 108
Gerasimov, M. R., Franceschi, M., Volkow, N. D., Rice, O., Schiffer, W. K., & Dewey, S. L. (2000) · Synapse · doi:10.1002/1098-2396(20001215)38:4<432::aid-syn8>3.0.co;2-q · Cited by 95
“In contrast, coadministration of nicotine and the higher (10 mg/kg) dose of MP produced an increase of 1325% above baseline that was clearly synergistic (Fig.”
BackgroundSelf-citationDing, Y., Lin, K., Garza, V., Carter, P., Alexoff, D., Logan, J., Shea, C. E., Xu, Y., & King, P. T. (2003) · Synapse · doi:10.1002/syn.10281 · Cited by 90
Self-citationWolraich, M. L., & Doffing, M. (2004) · CNS Drugs · doi:10.2165/00023210-200418040-00004 · Cited by 102
Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review
Jaeschke, R. R., Sujkowska, E., & Sowa-Kućma, M. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05946-0 · Cited by 126
Grow, D. A., McCarrey, J. R., & Navara, C. S. (2016) · Stem Cell Research · doi:10.1016/j.scr.2016.08.013 · Cited by 95
Koeppe, R. A., Frey, K. A., Kuhl, D. E., & Kilbourn, M. R. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199912000-00011 · Cited by 77
Davids, E., Zhang, K., Tarazi, F. I., & Baldessarini, R. J. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0962-5 · Cited by 82
“…brain imaging found that competition of [11C]d-methylphenidate to DA-rich CPu tissue in human brain was much greater than that of [11C]l–methylphenidate (tracer doses for both 6–7 mCi), with much greater enantiomeric selectivity than was found in cerebral cortex or cerebellum (Ding et al. 1997).”
BackgroundPrince, J. B. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.002 · Cited by 76
“Studies revealed that the primary active form of MPH is the d-threo isomer [23–25].”
BackgroundMarkowitz, J. S., & Patrick, K. S. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181733560 · Cited by 74
“5).(58) These findings in humans are consistent with most animal studies of the distribution of MPH enantiomers and strongly suggest that the pharmacological specificity of MPH in ameliorating ADHD symptoms resides solely in the d-enantiomer.”
BackgroundMethodResultInfluentialCalipari, E. S., Huggins, K. N., Mathews, T. A., & Jones, S. R. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.07.008 · Cited by 73
“There are some cross species comparisons using PET imaging and dopamine transporter (DAT) occupancy in humans, baboons and rats (Ding et al., 1997; Fowler et al., 1998), however, there is limited information on region specific DA kinetic parameters, such as release and uptake (Cragg et al., 2000,…”
BackgroundNew Formulations of Stimulants for Attention-Deficit Hyperactivity Disorder: Therapeutic Potential
Connor, D. F., & Steingard, R. J. (2004) · CNS Drugs · doi:10.2165/00023210-200418140-00005 · Cited by 79
Ding, Y., Lin, K., Logan, J., Benveniste, H., & Carter, P. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03202.x · Cited by 67
Self-citationMethylphenidate modulates cerebral post-stroke reorganization
Tardy, J., Pariente, J., Léger, A., Dechaumont-Palacin, S., Gerdelat, A., Guiraud, V., Conchou, F., Albucher, J., Marqué, P., Franceries, X., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.07.014 · Cited by 69
Virdee, K., Cumming, P. D., Caprioli, D., Jupp, B., Rominger, A., Aigbirhio, F. I., Fryer, T. D., Riss, P. J., & Dalley, J. W. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.01.009 · Cited by 64
Balcioglu, A., Ren, J.-Q., McCarthy, D., Spencer, T. J., Biederman, J., & Bhide, P. G. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.025 · Cited by 60
“Such administration can cause rapid rise in plasma and brain methylphenidate levels, which can reach peaks 5–10 times those seen in patients taking therapeutic doses of methylphenidate orally as ADHD treatment (Gerasimov et al., 2000; Kuczenski and Segal, 2002, 2005; Patrick and Markowitz, 1997).”
BackgroundInfluentialElectroencephalographic Biofeedback in the Treatment of Attention-Deficit/Hyperactivity Disorder
Monastra, V. J., Lynn, S. J., Linden, M., Lubar, J. F., Gruzelier, J. H., & Vaque, T. J. L. (2006) · Journal of Neurotherapy · doi:10.1300/j184v09n04_02 · Cited by 72
Long-Term Effectiveness and Safety of Dexmethylphenidate Extended-Release Capsules in Adult ADHD
Adler, L. A., Spencer, T., McGough, J. J., Jiang, H., & Muniz, R. (2009) · Journal of Attention Disorders · doi:10.1177/1087054708320397 · Cited by 53
“In adults, d-MPH binds specifically to dopamine transporters primarily in the basal ganglia, whereas 1-MPH binding is mainly nonspecific (Ding et al., 1997).”
BackgroundBrain kinetics of methylphenidate (Ritalin) enantiomers after oral administration
Ding, Y., Gatley, S. J., Thanos, P. K., Shea, C., Garza, V., Xu, Y., Carter, P., King, P., Warner, D., Taintor, N. B., et al. (2004) · Synapse · doi:10.1002/syn.20046 · Cited by 53
“In our previous studies, after the i.v. administration of [11C]d-threo-MP or [11C]l-threo-MP, regions of interest (ROIs) of the baboon brain were clearly defined and were drawn directly on the PET scans (Ding et al., 1997).”
BackgroundMethodResultInfluentialSelf-citationHeal, D. J., Gosden, J., & Smith, S. L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.06.012 · Cited by 58
Methylphenidate: Established and Expanding Roles in Symptom Management
Prommer, E. (2012) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909111427029 · Cited by 50
Doudet, D. J., Rosa‐Neto, P., Munk, O. L., Ruth, T. J., Jivan, S., & Cumming, P. D. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.09.044 · Cited by 50
Lepelletier, F.-X., Tauber, C., Nicolas, C., Solinas, M., Castelnau, P., Belzung, C., Emond, P., Cortese, S., Faraone, S. V., Chalon, S., et al. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu044 · Cited by 50
The impact ofCES1genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects
Stage, C., Jűrgens, G., Guski, L. S., Thomsen, R., Bjerre, D., Ferrero‐Miliani, L., Lyauk, Y. K., Rasmussen, H. B., & Dalhoff, K. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13237 · Cited by 43
Drug therapy of attention deficit hyperactivity disorder: Current trends
Sousa, A. D., & Kalra, G. (2012) · Mens Sana monographs · doi:10.4103/0973-1229.87261 · Cited by 52
“It was later recognised that the erythro form of MPH was responsible for the cardiovascular side effects of MPH, and thus MPH has been manufactured as an equal mixture of D and L-threo MPH. Studies have revealed that the D form is the primary active form of MPH (Ding et al., 1997 [31] , 2004 [32] ).”
An improved radiosynthesis of [18F]AV-133: a PET imaging agent for vesicular monoamine transporter 2
Zhu, L., Liu, Y., Plöessl, K., Lieberman, B. P., Liu, J., & Kung, H. F. (2009) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2009.10.005 · Cited by 41
Frölich, J., Banaschewski, T., Döpfner, M., & Görtz‐Dorten, A. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.922542 · Cited by 41
“For example, PET studies have demonstrated higher striatal uptake, a higher striatal-to-cerebellar ratio and a higher ratio for specific binding of radiolabeled d-MPH, whereas the l-MPH isomer binding was mostly unspecific [49,50].”
BackgroundHuff, J. K., & Davies, M. I. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(02)00196-6 · Cited by 36
Effects of methylphenidate on basic and higher-order oculomotor functions
Allman, A.-A., Ettinger, U., Joober, R., & O’Driscoll, G. A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112446531 · Cited by 36
Pharmacokinetic Characterization of [18F]UCB-H PET Radiopharmaceutical in the Rat Brain
Becker, G., Warnier, C., Serrano, M. E., Bahri, M. A., Mercier, J., Lemaire, C., Salmon, E., Luxen, A., & Plenevaux, A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00235 · Cited by 31
Kinetic modeling of [99mTc]TRODAT-1: a dopamine transporter imaging agent.
Kushner, S. A., McElgin, W., Kung, M. P., Mozley, P. D., Plößl, K., Meegalla, S. K., Mu, M., Dresel, S. H. J., Vessotskie, J. M., Lexow, N., et al. (1999) · PubMed · Cited by 33
d-Methylphenidate is non-genotoxic in in vitro and in vivo assays
Teo, S. K., San, R. H. C., Wagner, V. O., Gudi, R., Stirling, D., Thomas, S. D., & Khetani, V. D. (2003) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/s1383-5718(03)00053-6 · Cited by 33
The perinatal and postnatal toxicity of d-methylphenidate and d,l-methylphenidate in rats
Teo, S. K., Stirling, D., Thomas, S. D., Hoberman, A. M., Christian, M. S., & Khetani, V. D. (2002) · Reproductive Toxicology · doi:10.1016/s0890-6238(02)00044-8 · Cited by 32
D‐methylphenidate and D,L‐methylphenidate are not developmental toxicants in rats and rabbits
Teo, S. K., Stirling, D. I., Hoberman, A. M., Christian, M. S., Thomas, S. D., & Khetani, V. D. (2003) · Birth Defects Research Part B: Developmental and Reproductive Toxicology · doi:10.1002/bdrb.10018 · Cited by 32
Yang, X., Morris, S. M., Gearhart, J. M., Ruark, C. D., Paule, M. G., Slikker, W., Mattison, D. R., Vitiello, B., Twaddle, N. C., Doerge, D. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106101 · Cited by 35
Hou, H., Wang, C., Jia, S., Hu, S., & Tian, M. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-014-1469-5 · Cited by 36
“A PET imaging study using pretreatment with MP showed a marked decrease of [(11)C] d-threo-MP binding in the human brain([68]).”
MethodQuinn, D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181744aa6 · Cited by 33
“In terms of racemic methylphenidate, studies have demonstrated that the d-enantiomer d-MPH is the pharmacologically active component.(12) Animal models provide evidence that the binding of d,l-MPH to the DAT is selective for the d-MPH enantiomer.”
BackgroundNeurobehavioral effects of racemic threo-methylphenidate and its d and l enantiomers in rats
Teo, S. K., Stirling, D., Thomas, S. D., & Khetani, V. D. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)01073-0 · Cited by 30
A 90-Day Oral Gavage Toxicity Study of d-Methylphenidate and d, I-Methylphenidate in Beagle Dogs
Teo, S. K., Stirling, D., Thomas, S. D., Evans, M. G., & Khetani, V. D. (2003) · International Journal of Toxicology · doi:10.1080/10915810305100 · Cited by 30
Moen, M. D., & Keam, S. J. (2009) · CNS Drugs · doi:10.2165/11201140-000000000-00000 · Cited by 27
Narendran, R., Frankle, W. G., Mason, N. S., Laymon, C. M., Lopresti, B. J., Price, J. C., Kendro, S., Vora, S., Litschge, M. Y., Mountz, J. M., et al. (2009) · Synapse · doi:10.1002/syn.20633 · Cited by 28
Brams, M., Mao, A. R., & Doyle, R. L. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.09.1909 · Cited by 25
Thomsen, R., Rasmussen, H. B., & Línnet, K. (2012) · Journal of Analytical Toxicology · doi:10.1093/jat/bks065 · Cited by 25
Transport across the blood-brain barrier: stereoselectivity and PET-tracers
Luurtsema, G., DELANGE, E., Lammertsma, A. A., & Franssen, E. J. F. (2004) · Molecular Imaging and Biology · doi:10.1016/j.mibio.2004.06.008 · Cited by 24
Wang, Y., Li, W., Liu, T., Xu, L., Guo, Y., Ke, J., Li, S., & Li, H. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.109737 · Cited by 23
Fakayode, S. O., BUSCH, M., & BUSCH, K. (2005) · Talanta · doi:10.1016/j.talanta.2005.08.018 · Cited by 23
Saba, W., Valette, H., Peyronneau, M., Coulon, C., Ottaviani, M., Chalon, S., Dollé, F., Emond, P., Halldin, C., Helfenbein, J., et al. (2006) · Synapse · doi:10.1002/syn.20337 · Cited by 23
“…[18F]GBR-13119 (Kilbourn et al., 1989), [11C]-3b-(4-iodophenyl)tropane2b-carboxylic acid isopropyl ester (Hume et al., 1996), [11C]methylphenidate (Ding et al., 1997, Volkow et al., 2001), and several tropane derivatives such as carbon-11 and fluorine-18 labeled…”
BackgroundMethodWeiss, M. D., Wasdell, M. B., & Patin, J. R. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000138352.06229.b0 · Cited by 22
Ebert, K. E., Griem, P., Weiß, T., Brüning, T., Hayen, H., Koch, H. M., & Bury, D. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03704-7 · Cited by 21
“…may show differences in both pharmacodynamics and pharmacokinetics (Berners-Price and Kuchel 1990; Cleare and Hoeschele 1973; Chan et al. 1972; Ding et al. 1997), and indeed, we showed in a recently published oral metabolism study (Ebert et al. 2022) that the oral bioavailability of c HMS was…”
BackgroundZhu, H., Patrick, K. S., Straughn, A. B., Reeves, O. T., Bernstein, H., Shi, J., Johnson, H. J., Knight, J. M., Smith, A. T., Malcolm, R. J., et al. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000721 · Cited by 24
Positron Emission Tomography Molecular Imaging of Dopaminergic System in Drug Addiction
Hou, H., Tian, M., & Zhang, H. (2012) · The Anatomical Record · doi:10.1002/ar.22457 · Cited by 21
“…of cocaine) to the DAT, suggesting that [11C] D-threo-MP was a useful PET tracer for imaging the presynaptic dopaminergic neuron (Ding et al., 1995; Ding et al., 1997) and had been used to study the humans after methylphenidate was used (Ding et al., 1997) or with alcohol addiction (Volkow et al.,…”
BackgroundMethodSilva, R., Tilker, H. A., Cecil, J. T., Kowalik, S., Khetani, V., Faleck, H., & Patin, J. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.555 · Cited by 18
Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder
McGough, J. J., Pataki, C. S., & Suddath, R. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.4.437 · Cited by 17
Bolfer, C. P. M. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2014.tde-24022015-115036 · Cited by 19
Quantitative structure–activity relationship studies of threo-methylphenidate analogs
Misra, M., Shi, Q., Ye, X., Gruszecka‐Kowalik, E., Bu, W., Liu, Z., Schweri, M. M., Deutsch, H. M., & Venanzi, C. A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.034 · Cited by 18
Imaging the functioning human brain
Weng, X., Ding, Y., & Volkow, N. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11073 · Cited by 16
Self-citationToxicokinetic assessment of methylphenidate (Ritalin®) in a 13‐week oral toxicity study in dogs
Bakhtiar, R., Ramos, L., & Tse, F. L. S. (2003) · Biomedical Chromatography · doi:10.1002/bmc.290 · Cited by 15
Zhang, X., Wu, H., Yin, X., Li, L.-H., Wang, J., Chen, Y. M., Kang, C., & Yu, R. (2012) · Analytical Methods · doi:10.1039/c2ay25975c · Cited by 14
Connor, D. F. (2005) · Contemporary clinical neuroscience · doi:10.1385/1-59259-891-9:487 · Cited by 15
Zhang, J., Deng, Y., Fang, J., & McKay, G. (2003) · Pharmaceutical Research · doi:10.1023/b:pham.0000003389.77585.be · Cited by 14
Stereoselective neuroimaging in vivo
Smith, D. F., & Jakobsen, S. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.02.008 · Cited by 14
Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder
Liu, F., Minami, H., & Silva, R. R. (2006) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2006.2.4.467 · Cited by 15
“…emission tomography (PET) or microdialysis have not only become a valuable technique to analyze pharmacodynamics of MPH and its enantiomers (Ding et al 1995, 1997, 2004; Gatley et al 1995; Logan et al 1996, 2001; Volkow et al 2002; Kilbourn 2004), but also served as an effective tool to…”
InfluentialTomasi, D. G., Manza, P., Logan, J., Kojori, E. S., Yonga, M.-V., Kroll, D. S., Feldman, D. E., McPherson, K. L., Biesecker, C. L., Dennis, E., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04545-3 · Cited by 11
Self-citationApplication of chiral chromatography in radiopharmaceutical fields: A review
Moein, M. M., & Tran, T. A. (2020) · Journal of Chromatography A · doi:10.1016/j.chroma.2020.461611 · Cited by 12
Highlights of PET studies on chiral radiotracers and drugs at Brookhaven
Ding, Y., & Fowler, J. S. (2003) · Drug Development Research · doi:10.1002/ddr.10221 · Cited by 11
“The ability to label dl-threo-MP as well as the individual enantiomers, d-threo and l-threo-MP, with carbon-11 provided the opportunity to compare them directly in the human brain with PET [Ding et al., 1997].”
BackgroundSelf-citationTuerck, D., Appel‐Dingemanse, S., Maboudian, M., Pommier, F., Wang, Y., & Sedek, G. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006293757 · Cited by 11
“Furthermore, d-MPH, but not l-MPH, is selectively bound to the dopamine transporter in the basal ganglia, the putative site of action, after intravenous administration of equimolar doses of the pure enantiomers.(8,9) Both MPH enantiomers are primarily metabolized by carboxylesterase CES1A1 deesterification to the resp…”
BackgroundIngle, J. R., Busch, K. W., & BUSCH, M. A. (2007) · Talanta · doi:10.1016/j.talanta.2007.11.056 · Cited by 11
Optimization of preparative electrophoretic chiral separation of ritalin enantiomers
Schneiderman, E., Gratz, S. R., & Stalcup, A. M. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(01)00572-6 · Cited by 11
The use of psychostimulants in palliative and supportive treatment of cancer patients
Kaminski, M., & gren, P. S. (2007) · Advances in Palliative Medicine · Cited by 10
Metadata
- Authors
- Ding, Y.-S., Fowler, J. S., Volkow, N. D., Dewey, S. L., Wang, G.-J., Logan, J., Gatley, S. J., & Pappas, N.
- Affiliations
- Brookhaven National Laboratory (US)
- Venue
- Psychopharmacology
- Published
- 1997-05-15
- Volume
- 131
- Issue
- 1
- Pages
- 71-78
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1990494131
- Cited by
- 157
- References
- 31
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 2 · 2018: 2 · 2017: 5 · 2016: 3 · 2015: 4 · 2014: 7 · 2013: 4 · 2012: 11
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- green
- zenodo.org
- Licence
- public-domain
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, public-domain)
- Funders
- National Institutes of Health (2r01ns015380-27, 5p01ns015638-15)
- National Institute on Drug Abuse (DA-06278, R01DA006278)
- National Institute of Neurological Disorders and Stroke (NS15638, NS 15380)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- methylphenidate, enantiomers, chiral drugs, pharmacokinetics, brain distribution, striatal dopamine, basal ganglia, cerebellum, GBR 12909, attention deficit hyperactivity disorder, PET radiotracer, microdialysis, baboon brain, human brain
- MeSH terms
- Aged, Animals, Brain, Female, Humans, Male, Methylphenidate, Middle Aged, Papio, Radioligand Assay, Stereoisomerism, Tomography, Emission-Computed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.